Form 4: Rapport Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Krishnaswamy Yeleswaram, Chief Development Officer of Rapport Therapeutics, was granted stock options for 110,000 shares on February 3, 2025.
Summary
- Krishnaswamy Yeleswaram, the Chief Development Officer of Rapport Therapeutics, was granted stock options to purchase 110,000 shares of common stock.
- The transaction occurred on February 3, 2025.
- The exercise price of the stock options is $16.60 per share.
- The options vest in 48 equal monthly installments starting January 1, 2025, contingent upon continued service.
- The options expire on February 3, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and indicates confidence in the executive's ability to contribute to the company's success. The vesting schedule promotes long-term alignment.
Positives
- The granting of stock options to the Chief Development Officer aligns his interests with those of the shareholders.
- The vesting schedule incentivizes continued service and contribution to the company's success.
Future Outlook
The vesting schedule suggests a long-term commitment expected from the Chief Development Officer.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
- The size of the grant and the vesting schedule are typical for executives at this level, aligning with industry practices for incentivizing long-term performance.
- Comparing the exercise price and vesting schedule to similar companies like Biohaven or Karuna Therapeutics would provide further context on the competitiveness of the compensation package.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning executive interests with company performance.
- Employees may see this as a positive indicator of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| January 1, 2025 | Start date for monthly vesting of stock options. |
| February 3, 2025 | Date of the stock option grant. |
| February 4, 2025 | Date of the Form 4 filing. |
| February 3, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.